RxDoctor Payments Data

Laura Ryan, MD

Internal Medicine · Downey, CANPI 1114344173

Payments from drug & device makers

$13,586in general payments, 2019–2025

Across 678 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Lilly USA, LLC$1K
  • AstraZeneca$1K
  • GSK$947
  • Merck$827
  • Pfizer$795
  • plus $6K from 53 others

What the payments were for

  • Food & beverage$13,523100%
  • Education$620%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)164$2,960
Lilly USA, LLC63$1,176
AstraZeneca66$1,152
GSK41$947
Merck41$827
Pfizer40$795
Boehringer Ingelheim21$541
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC25$482
Novo Nordisk20$422
Novartis21$400
Bayer17$351
Amarin Pharma, Inc.14$325
Amgen7$257
Scilex Pharmaceuticals Inc.11$241
Otsuka America Pharmaceutical, Inc.8$205
Dexcom, Inc.7$165
Phathom Pharmaceuticals, Inc.6$153
Biohaven Pharmaceuticals, Inc.7$142
Johnson & Johnson11$125
Ardelyx, Inc.4$124
Eisai Inc.6$118
Biohaven Pharmaceutical Holding Company Ltd.4$102
Medtronic1$98
Almatica Pharma LLC5$85
Xeris Pharmaceuticals, Inc.4$83
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$76
Exact Sciences3$74
Ironwood Pharmaceuticals, Inc4$73
Shield Therapeutics Inc4$73
Esperion Therapeutics, Inc.3$69
Radius Health, Inc.3$60
Boston Scientific2$56
Teva Pharmaceuticals USA, Inc.3$55
Mylan Specialty L.p.3$53
Supernus Pharmaceuticals, Inc.3$47
Shire North American Group Inc2$47
E.r. Squibb & Sons, L.L.C.2$46
Astellas Pharma US Inc2$45
Takeda Pharmaceuticals U.S.A., Inc.2$43
Smith+Nephew2$42
Sanofi-aventis U.S. LLC2$38
Averitas Pharma Inc.1$35
Idorsia Pharmaceuticals US Inc2$34
Azurity Pharmaceuticals, Inc.2$33
Sumitomo Pharma America, Inc.1$30
Philips North America LLC1$28
Ascensia Diabetes Care US Inc.1$26
Aimmune Therapeutics, Inc.1$25
Abbott1$24
Myriad Genetic Laboratories, Inc.1$24
Genentech USA, Inc.1$23
Axsome Therapeutics, Inc.1$21
Medicure Pharma Inc.1$20
Dermira, Inc.1$16
Currax Pharmaceuticals LLC1$15
Optinose US, Inc.1$15
Otsuka Pharmaceutical Development & Commercialization, Inc.1$15
Optos, Inc.1$15
Kyowa Kirin, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,586 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$69,148
Medicare patients
128
Services billed
702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide251$352,961
TrulicityDulaglutide188$311,485
JardianceEmpagliflozin139$194,686
FarxigaDapagliflozin Propanediol152$176,243
JanuviaSitagliptin Phosphate115$113,896
LinzessLinaclotide86$106,855
EliquisApixaban88$84,245
MounjaroTirzepatide31$51,550
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$46,907
EntrestoSacubitril/Valsartan21$29,718
Xigduo XrDapaglifloz Propaned/Metformin16$21,211
TradjentaLinagliptin29$15,113
InvokanaCanagliflozin18$12,383
JanumetSitagliptin Phos/Metformin Hcl14$11,860
VascepaIcosapent Ethyl34$11,846

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humulin 70-30$1,176$372,100268 claims
Novo NordiskOzempic$422$352,961251 claims
Boehringer IngelheimJardiance, Tradjenta$541$209,799168 claims
AstraZenecaFarxiga$1,152$176,243152 claims
MerckJanuvia, Janumet$827$125,757129 claims
AbbVieLinzess, Synthroid$2,960$109,560113 claims
PfizerEliquis$795$84,24588 claims
GSKTrelegy Ellipta, Breo Ellipta$947$51,16777 claims
NovartisEntresto$400$29,71821 claims
Johnson & JohnsonInvokana$125$12,38318 claims
Sanofi-aventis U.S. LLCLantus$38$4,74125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Downey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →